Miltenyi Biotec Receives ‘Special Recognition Award’ for Pioneering Work in Cell & Gene Therapy at BioSpectrum India ...

The CVCT Forum is an annual, invite-only workshop that aims to cultivate a multi-stakeholder exchange to enhance clinical trials, streamline regulatory approval processes, and facilitate the ...

Novartis’ Itvisma wins FDA approval as the first gene replacement therapy for spinal muscular atrophy (SMA) patients age 2 ...

Discover why Cryoport (CYRX) offers deep value for investors as the leader in temperature-controlled logistics for cell and ...

The U.S. Food and Drug Administration has approved Novartis' gene therapy for patients with a rare muscle disorder, the drugmaker said on Monday. The therapy, branded as Itvisma, was approved for the ...

A Mississippi mother and a filmmaker discuss the trials and triumphs of supporting the discovery of a gene-therapy program for a rare disease in the US.

ITVISMA is a prescription gene therapy used to treat adults and children 2 years of age and older with spinal muscular atrophy (SMA). ITVISMA is given as a one-time intrathecal injection. What is the ...

Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function improvements.

Researchers discovered that a tiny structural feature of the enzyme GPX4 helps keep neurons safe. A rare mutation removes ...